DUET Trial: Low-Sodium Oxybate Significantly Consolidates Nighttime Sleep Architecture in Narcolepsy
The phase‑4 DUET trial showed that low‑sodium oxybate (LXB, Xywav) markedly consolidates nighttime sleep in narcolepsy type 1 and type 2 patients. Objective polysomnography recorded a 45‑minute increase in deep N3 sleep, 13 fewer stage transitions and three fewer awakenings per night. Daytime symptoms improved dramatically, with the Epworth Sleepiness Scale falling 7.7 points and 93% of participants reporting overall condition improvement. Safety remained consistent, with mild‑to‑moderate adverse events in 61.8% and no serious events, while delivering 92% less sodium than traditional sodium oxybate.
Human Antibodies Identified That Have Potential To Prevent and Treat Measles Virus
Scientists at the La Jolla Institute for Immunology have isolated the first human monoclonal antibodies that can neutralize measles virus. The antibodies, derived from a vaccinated donor, bind the virus' hemagglutinin and fusion proteins, blocking entry into cells. In a...
NACDS Submits Comments to FDA on Expanding Access to Nonprescription Drugs
The National Association of Chain Drug Stores (NACDS) submitted formal comments to the FDA supporting the agency’s initiative to expand over‑the‑counter (OTC) drug availability. NACDS highlighted the potential for greater convenience, preventive care, and timely treatment if prescription‑only therapies move...
Stem Cell-Derived Islet Therapies Target Type 1 Diabetes Challenges
Sana Biotechnology is leveraging hypoimmune cell engineering to create allogeneic, stem‑cell‑derived pancreatic islet‑like cells that can evade both adaptive and innate immune attacks. The company aims to deliver a single intramuscular injection that restores normal blood‑sugar control for type 1 diabetes...
Aptevo Reports Strong Remission Data in Frontline AML Trial as RAINIER Study Advances Toward Phase 2
Aptevo Therapeutics disclosed Phase 1b data from its RAINIER trial, showing mipletamig combined with venetoclax and azacitidine achieved an 87% clinical benefit rate and an 81% composite remission rate in 31 frontline AML patients. The regimen produced a 65% complete remission...
Ingevity Corporation (NGVT) Q1 2026 Earnings Call Transcript
Ingevity Corporation posted a strong first‑quarter 2026 performance, delivering $210 million in revenue, an 8% year‑over‑year increase, and adjusted EBITDA of $45 million, expanding its margin to 12%. The company unveiled a new high‑performance silica product line aimed at electric‑vehicle battery applications,...
Feds Expand Pharmacy Benefit Program
The U.S. Department of Labor announced an expansion of pharmacy‑benefit reforms under the Federal Employees’ Compensation Act, extending cost‑saving measures to workers covered by the Black Lung, Longshore and Harbor, and Energy Employees compensation programs. The initiative builds on 2018...
Just ‘Stay Alive for the Next 10 Years’ – Anti-Ageing Drugs Are Coming, Says Billionaire Investor
Billionaire investor Jim Mellon told attendees at Spear’s 500 Live that the first truly anti‑ageing drugs could hit the market within a decade. He highlighted clinical‑stage senolytics, partial genetic reprogramming and repurposed weight‑loss medicines as the leading candidates to halt...
EnGene's Shares Crash on Updated Pivotal Bladder Cancer Data
EnGene Therapeutics reported Phase 2 data for its experimental bladder‑cancer therapy that revealed a modest 5% objective response rate and safety signals in more than half of patients. The results triggered an 80% plunge in the Canadian biotech’s stock, wiping...
Blackstone Puts $250M Into Anagram to Tackle Cystic Fibrosis Complication
Blackstone Life Sciences announced a $250 million investment in Anagram, a biotech developing a novel therapy for a cystic fibrosis complication. The capital, drawn from one of the industry’s largest private life‑science funds, will accelerate Anagram’s late‑stage clinical trials, manufacturing scale‑up,...
Anesthetic and Analgesic Drug Products Advisory Committee Charter
The FDA has established the Anesthetic and Analgesic Drug Products Advisory Committee to provide expert advice on the safety and efficacy of marketed and investigational analgesics, including abuse‑deterrent opioids and anesthetic products. The charter, approved April 23, 2026, outlines a...
Entrada Stock Falls on Duchenne Data; Wegovy Expands Access
Entrada Therapeutics reported topline results from its Duchenne muscular dystrophy (DMD) cohort of six patients, showing no meaningful functional improvement. The disappointing data sent Entrada's shares down roughly 15% in after‑hours trading. Meanwhile, Novo Nordisk announced expanded payer coverage for...
Insmed Tanks On Its Most Important Launch; Why Analysts Remain Bullish
Insmed’s newly launched lung drug Brinsupri posted first‑quarter sales of $208 million, beating sell‑side forecasts but falling short of the $230 million buy‑side target. The miss triggered a near‑17% plunge in the stock, sending shares to $114.25, their lowest level since August....
FDA Reverses Course on Atara, Pierre Fabre’s Twice-Rejected Cell Therapy After Prasad’s Exit
Atara Biotherapeutics and Pierre Fabre’s EBV‑positive PTLD cell therapy Ebvallo received a regulatory U‑turn after FDA CBER director Vinay Prasad stepped down. The agency now says a single‑arm study with an appropriate historical control can satisfy the “adequate and well‑controlled” requirement, allowing...
Electric‐Eel‐Inspired Ionic Power Source Microneedles With Self‐Reporting Structural Colors for Wound Healing
Researchers have engineered ionic power source microneedles (IPSMs) that combine electric‑eel‑inspired ion transport with chameleon‑like structural colors for wound care. The three‑layer device creates an internal K⁺‑driven electric field, delivering electrical stimulation that accelerates tissue repair. Integrated silver nanoparticles provide...
Transforming CTMS: An Operating Layer for Real-Time Trial Execution
Clinical trial management systems (CTMS) are evolving from static record‑keeping tools into an operating layer that adds real‑time, AI‑driven reasoning to coordinate complex, multi‑system studies. The article highlights that Phase III trials now span a median of more than ten countries,...
Funding Roundup: Kanvas Biosciences, LTZ Therapeutics Draw Investor Interest for Next-Generation Cancer Immunotherapies
Kanvas Biosciences and LTZ Therapeutics announced a combined $86 million financing round to accelerate next‑generation cancer immunotherapies. Kanvas closed a $48 million Series A to push its microbiome‑based platform and the lead candidate KAN‑001 toward clinical trials. LTZ secured $38 million to expand its...
Amgen Adds $300M to Puerto Rico Budget; Novartis to Exit Oral Drug Factory in Germany
Amgen announced an additional $300 million investment to expand its manufacturing footprint in Puerto Rico, bringing its total U.S. capital outlay to nearly $2 billion over the past year. The funding will support new bioprocessing lines and increase the island’s capacity for...
Breaking Down Frontline BTK Inhibitor Selection in CLL: Kerry Rogers, MD
When choosing a frontline Bruton tyrosine kinase (BTK) inhibitor for chronic lymphocytic leukemia, clinicians currently rely on FDA‑approved covalent agents, with acalabrutinib and zanubrutinib favored for their superior cardiovascular safety over ibrutinib. Emerging data from the 2025 ASH meeting show...
STAT+: Pharmalittle: We’re Reading About Sanofi and an FDA Voucher, FDA Rethinking a Rejection, and More
Sanofi asked the FDA to withdraw its type 1 diabetes antibody teplizumab from the new fast‑track voucher program after Center for Drug Evaluation and Research director Tracy Beth Høeg publicly challenged a staff decision to approve the drug. The agency missed...
Entrada Crashes as Duchenne Therapy Comes in ‘Below Expectations’ in Early Study
Entrada Therapeutics reported that its investigational oligonucleotide ENTR‑601‑44 raised dystrophin levels by 2.36% in the first cohort of its Phase 1/2 ELEVATE‑44‑201 trial, far below the company’s double‑digit target. The modest protein increase triggered a 50% plunge in the Boston‑based biotech’s...
Podcast: Autonomous Labs Redefine the Role of Biopharma Researchers
Autonomous laboratories, integrating robotic hardware with AI-driven decision making, are emerging as a transformative force in biopharma R&D. In a GlobalData Media podcast, Frankie Fattorini interviewed Jason Kelly, CEO of Ginkgo Bioworks, who described how these labs can conduct experiments with unprecedented precision...
STAT+: FDA Revisits a Rare Cancer Treatment It Rejected a Few Months Ago
The FDA has announced it will re‑evaluate a rare‑cancer therapy it dismissed just months earlier, citing new data submitted by the drug’s sponsor. The treatment, aimed at a subtype of metastatic sarcoma, originally failed to meet the agency’s efficacy benchmarks...
Amylyx Pharmaceuticals Q1 Earnings Call Highlights
Amylyx Pharmaceuticals reported that the Phase 3 LUCIDITY trial of its GLP‑1 antagonist avexitide completed dosing and is on track for a top‑line readout in Q3 2026. The company launched a U.S. expanded access program to treat up to 250 adults with...
Atara, Pierre Fabre's Cell Therapy to Get Another Shot at FDA Approval
Atara Biotherapeutics and Pierre Fabre Pharmaceuticals are reviving a T‑cell therapy that was rejected twice by the FDA. Regulators have signaled willingness to base a new approval decision on data from a Phase 3 trial, a departure from the earlier requirement...
Wolfe Research Says Market Reaction on Eli Lilly (LLY) Foundayo Report Appears Overdone
Wolfe Research says the market overreacted to an FDA adverse‑event report on Eli Lilly’s GLP‑1 drug Foundayo. Lilly determined the serious hepatic failure case was not reasonably related to the product. Shares fell about 3% in pre‑market trading, yet analysts kept...
Lilly, Gilead Lead Pharma’s M&A Boom
Pharma M&A activity surged in early 2026, with 24 deals announced by April and upfront payments topping $64 billion—almost triple the $24.5 billion recorded in the same period last year. The boom is driven by companies racing to refill pipelines before a...
The Rise of Trispecific Antibodies: Biopharma’s Next Big Bet After Bispecifics
Trispecific antibodies are emerging as the next wave of multispecific therapeutics, extending the success of bispecifics by simultaneously engaging three targets. More than 100 candidates are now in clinical trials, with major players such as Pfizer, Sanofi, AbbVie and Johnson...
Treatment-Resistant IBD May Benefit From New Combo Antibody Therapy
Phase 2b DUET‑Crohn’s and DUET‑UC trials, funded by Johnson & Johnson, tested the fixed‑dose co‑antibody JNJ‑4804 (guselkumab + golimumab) in patients whose IBD had failed prior advanced therapies. In ulcerative colitis, JNJ‑4804 matched guselkumab’s efficacy and outperformed golimumab, while in Crohn’s disease the highest dose...
Bayer Reports P-III (REVEAL) Trial Data on Iodine 124 Evuzamitide to Diagnose Cardiac Amyloidosis
Bayer announced that its investigational PET/CT radiotracer I‑124 evuzamitide met the primary sensitivity and specificity endpoints in the Phase III REVEAL trial of 170 adults with suspected cardiac amyloidosis. The study compared the tracer to standard clinical diagnosis and achieved the...
Silence Therapeutics Highlights Recent Business Achievements and Reports First Quarter 2026 Financial Results
Silence Therapeutics reported Q1 2026 results, ending the quarter with $70.1 million in cash and a net loss of $15 million, a sharp improvement from the $28.5 million loss a year earlier. The company highlighted progress on its lead siRNA candidate divesiran, with Phase 2...
Unlocking Lithium’s Hidden Effects on Alzheimer’s Disease at the Cellular Level
A University of Eastern Finland team mapped lithium chloride’s cellular actions in Alzheimer’s models, showing it reduces Tau hyperphosphorylation at several key sites and reshapes kinase and Rho GTPase signaling. Phosphoproteomic analysis revealed lithium’s impact extends beyond the primary GSK‑3β...
Eli Lilly’s Mounjaro Becomes World’s Top-Selling Drug
Eli Lilly’s tirzepatide‑based drug Mounjaro has overtaken Merck’s Keytruda as the world’s top‑selling medication, posting $8.7 billion in Q1 2026. Combined with weight‑loss drug Zepbound, the tirzepatide platform generated $36.5 billion in 2025, outpacing Keytruda’s $31.6 billion annual sales. The shift reflects growing demand for...
NIH-Funded Study Suggests that Testosterone Suppresses Brain Tumor Growth in Males
A NIH‑funded study by Cleveland Clinic researchers found that loss of male hormones, especially testosterone, accelerates glioblastoma growth in mouse models by triggering inflammation and the hypothalamus‑pituitary‑adrenal (HPA) stress axis. Supplemental testosterone was associated with a 38% lower risk of...
Magic Mushroom Compound Shows Promise Against Cocaine Addiction
A randomized, double‑blind trial of psilocybin in 40 cocaine‑dependent adults, published in JAMA Network Open, found that 30% of participants receiving a single dose were completely abstinent after 180 days, compared with none in the placebo arm, and remaining users...
STAT+: Next-Gen Duchenne Drug From Entrada Disappoints
Entrada Therapeutics reported that its next‑generation exon‑skipping drug for Duchenne muscular dystrophy failed to achieve its primary efficacy endpoints in an early‑stage trial. The study showed only a modest rise in dystrophin levels, far below the thresholds set by the...
Entrada Shares Sink After Duchenne Drug Falls Short of Expectations
Entrada Therapeutics reported that its experimental Duchenne drug ENTR-601-44 generated only a 2.36‑point increase in dystrophin, far below the 10‑11% rise analysts had modeled. The shortfall sent the company’s shares tumbling more than 50% in pre‑market trading. By contrast, Avidity...
Angelini Fortifies Neurology Portfolio with $4.1B Buyout of Catalyst
Italian drugmaker Angelini Pharma announced a $4.1 billion acquisition of U.S.-based Catalyst Pharmaceuticals, adding its trio of FDA‑approved treatments for rare neurological disorders to Angelini’s portfolio. The deal brings Ingrezza, Firdapse and a third specialty drug under Angelini’s control, instantly expanding...
Roche to Acquire PathAI for ~$1.05B
Roche has signed a definitive agreement to acquire AI‑driven diagnostics firm PathAI for an estimated $1.05 billion, comprising $750 million upfront and up to $300 million in milestones. The deal, slated to close in the second half of 2026, builds on a partnership...
Scientists Discover Why Ozempic Works Better for some People
GLP‑1 drugs like Ozempic improve blood sugar and weight loss, but response varies. A Japanese study of 92 type‑2 diabetes patients found that those who overeat in response to external cues (appearance or smell) achieved greater weight loss and glucose...
What the FDA's Latest Proposal Means for Lilly, Novo, and Hims
The FDA has proposed removing tirzepatide and semaglutide from the 503B bulk‑drug list, effectively ending compounding of these high‑demand GLP‑1 therapies. Eli Lilly, whose tirzepatide‑based products posted 56% YoY revenue growth and a 28% full‑year 2026 outlook, and Novo Nordisk, facing a...
Trump Promised Cheaper Drugs. Some Prices Dropped. Many Others Shot Up.
President Trump’s second term has produced a series of high‑profile drug‑price initiatives, including the TrumpRx discount portal, voluntary "most‑favored‑nation" agreements with manufacturers, and accelerated biosimilar approvals. While a handful of cash‑pay patients see steep cuts on fertility drugs and GLP‑1...
Angelini Pharma to Acquire Catalyst Pharmaceuticals for ~$4.1B
Angelini Pharma announced a definitive agreement to acquire Catalyst Pharmaceuticals for $31.5 per share, valuing the deal at roughly $4.1 billion. The transaction, expected to close in the third quarter of 2026, marks Angelini’s first direct entry into the U.S. pharmaceutical...
Halozyme and Oruka Sign Agreement for Hypercon Technology
Halozyme’s Hypercon technology has entered an exclusive global licensing agreement with Oruka Therapeutics to develop ORKA-001, a biologic targeting the IL‑23p19 subunit for psoriasis and related inflammatory diseases. The deal provides Halozyme with an upfront cash payment, future milestone fees,...
Global Drugmakers Eye More China Biotech Deals After Record Year
Global pharmaceutical firms are intensifying their pursuit of Chinese biotech partners after 2025 set a record $135.7 billion in out‑licensing deals, nearly three times the 2024 total. Executives from Johnson & Johnson and Merck highlighted plans to expand on‑the‑ground resources and...
Fibrosis, IPF and the Search for Better Therapies
The BioSpace "Denatured" podcast episode spotlights the persistent challenges of idiopathic pulmonary fibrosis (IPF) and broader fibrotic diseases. Host Jennifer C. Smith‑Parker interviews Georg Vo Beiske, CEO of Tribune Therapeutics, and Jonas Hallén, CMO of Calluna Pharma, to dissect current treatment gaps and...
Macrophage‐Inspired Nanomedicines: Harnessing Innate Biology for Precision Therapy
The review outlines macrophage‑inspired nanomedicines that exploit three delivery platforms—whole macrophage carriers, macrophage‑membrane‑coated nanoparticles, and macrophage‑derived exosomes. By leveraging the cells’ natural homing, barrier‑penetrating and immunomodulatory traits, these systems aim to improve targeting of cancers, atherosclerosis and other inflammatory diseases....
Artera Secures FDA Clearance for AI-Based Breast Cancer Risk Tool
The U.S. Food and Drug Administration granted clearance to ArteraAI Breast, an AI‑driven digital pathology tool that combines digitized histopathology slides with clinical data to generate a risk score for distant metastasis in early‑stage hormone‑receptor‑positive/HER2‑negative breast cancer. The system stratifies...
Trends From the Trenches: The Capability Jump of AI and Its Impact
AI’s rapid capability jump is reshaping computational biology, especially bioinformatics pipelines such as RNA‑seq, single‑cell and spatial transcriptomics. While software firms report most code now AI‑assisted, biotech teams still write code manually, creating a clear adoption gap. Benchmarks—capability, task and...
WA Biotech Duo Takes Aim at Diabetes Beyond Ozempic
Australian biotech duo ProGenis Pharmaceuticals and Syngenis Labs are developing RNA‑based antisense therapies that target insulin resistance, a root cause of type‑2 diabetes, to complement GLP‑1 drugs. Syngenis is building Australia’s first GMP‑grade synthetic DNA/RNA manufacturing facility, expected to be...